np event 2254995 0E193A 1
Jan 20, 2025
- Jan 19, 2026

Unmet Needs in the Management of Atrial Fibrillation (AF)

EARNed Credits

0.5

AMA PRA Category 1 CreditsTM

CPE Contact Hours

CNE Contact Hours

Screenshot 2025-01-20 at 7.03.34 PM

Overview

Drs. Granger, Goodman, and Pollack provide an introduction to the Factor XI hypothesis of hemostasis-sparing anticoagulation, explaining the unlinking of hemostasis and thrombosis in a modern conception of the coagulation cascade. They provide a brief overview of the development of Factor XI and Factor XIa inhibitors to date in multiple therapeutic areas, and then focus on stroke prevention in atrial fibrillation, a burgeoning indication in which too many patients remain unprotected from thromboembolic events because of risk or fear of bleeding.  Finally, they introduce the ongoing Phase 3 LILAC TIMI 73 trial, which is comparing the monoclonal antibody Factor XI inhibitor abelacimab to placebo in patients with AF and moderate to high risk of stroke deemed unsuitable for currently available anticoagulants.

Who Should Attend

Cardiologists managing patients with AF who are unsuitable for conventional anticoagulation

Provided By

Course Faculty

Goodman
Shaun G. Goodman, MD, MSc, FCCS, FESC, FACC, FAHA
Associate Head, Division of Cardiology, St. Michael’s Hospital, Unity Health Toronto Professor, University of Toronto Co-Director, Canadian VIGOUR Centre Adjunct Professor, University of Alberta
Granger
Christopher B. Granger, MD, FACC, FAHA, FESC
Fred Cobb Distinguished Professor of Medicine, Professor of Nursing
Pollack
Charles Pollack, MD, FACEP, FAHA, FACC, FESC
Moderator Clinician-Scientist, Emergency Medicine, University of Mississippi Medical Center Clinical Trials Consultant to Anthos Therapeutics

Learning Objectives

1

Better understand current unmet needs in the provision of safe and effective stroke prevention for patients with atrial fibrillation

2

Introduction to the Factor XI inhibitors, a new class of anticoagulant with the potential to reduce bleeding risk

3

Review the types of patients who may be well suited for inclusion in the LILAC-TIMI 76 study

4

Learn about clinical trial sites in your region to which patients can be referred to determine eligibility

Course Agenda

1

A Review of Anticoagulation Therapy: Challenges and Lessons Learned

2

Understanding Factor XI and Thrombosis

3

Clinical Trial Data, Including an Analysis of LILAC-TIMI 76: Efficacy and Safety

4

Interpreting Inclusion Criteria and Best Practices for Referring Patients to the Trial

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity.

Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty Relationship Identified With:
Christopher B. Granger, MD Grants: Alnylam, Boehringer Ingelheim, Bristol Myers Squibb, FDA, Janssen, Lilly, Novartis, Pfizer, Philips, Roch

Consulting: Abbvie, Abiomed, AlnylamPharmaceuticals, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Cadrenal, CeleCore Therapueutics, HengRui, Janssen, Medscape, Medtronic Inc., Merck, NIH, Novo Nordisk, Novartis, Pfizer, Philips , REATA, Roche, Veralox

Stock or Stock Options: Tenac.io

Shaun G. Goodman, MD Research Grants and/or Speaker/Consulting Honoraria: Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, CYTE Ltd., Daiichi-Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals, Valeo Pharma

Salary Support/Honoraria: Canadian Heart Failure Society, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\ CIUSSS Centre-Ouest-de-l'Ile-de-Montreal, New York University Clinical Coordinating Centre, PERFUSE Research Institute, Peter Munk Cardiac Centre Clinical Trials and Translation Unit, Ted Rogers Centre for Heart Research, TIMI Study Group (Brigham Health)

Charles Pollack, MD

 

Research Grants and/or Speaker/Consulting Honoraria: Anthos; AstraZeneca; Cayuga; Huyabio; Idorsia; Provepharm; VarmX

Timothy Hayes, MD, PhD; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits TM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours (Provider #P0491).

AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of continuing pharmacy education credit (UAN #JA4008190-0000-25-001-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Anthos Therapeutics.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Anthos Therapeutics do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

 

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the Pre-Activity Questions
    3. Read or Review the activity content.
    4. Complete the Post-Activity Test Questions and Evaluation.
    5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com.

np event 2254995 0E193A 1
Jan 20, 2025
- Jan 19, 2026

Unmet Needs in the Management of Atrial Fibrillation (AF)

Related Webcast Courses

np document 888746 0E193A 5
Cardiology
Venous Thromboembolism - Risk Assessment
np document 888746 0E193A 5
Cardiology
Hypertrophic Cardiomyopathy: New Evidence, Updated Guidelines to Support Optimal Managemen...
np document 888746 0E193A 5
Cardiology
VTE and Anticoagulation – Guideline Updates for 2024